EVFMOTCPharmaceutical PreparationsUS GAAP · USD

Evofem Biosciences, Inc.

Evofem Biosciences, Inc. is a U.S.-based pharmaceutical company focused on commercializing women’s health products. Its core business centers on PHEXXI for pregnancy prevention and SOLOSEC for bacterial vaginosis and trichomoniasis, supported by telehealth and third-party commercialization channels.

Kysy yhtiöstä
Liikevaihto20,2milj. USD
+4,2 %v/v
Liikevoitto (EBIT)3,4milj. USD
+143,9 %v/v
EBIT-marginaali16,7%
+56,3 %-yks.v/v
Nettotulos0,4milj. USD
+104,4 %v/v
Vapaa kassavirta−2,0milj. USD
+48,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−150−100−50050milj. USD2020: 0,45 milj. USD2020: EBIT −104 milj. USD20202021: 8,2 milj. USD2021: EBIT −167 milj. USD20212022: 17 milj. USD2022: EBIT −84 milj. USD20222023: 18 milj. USD2023: EBIT −18 milj. USD20232024: 19 milj. USD2024: EBIT −7,7 milj. USD20242025: 20 milj. USD2025: EBIT 3,4 milj. USD2025203,4
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Women’s health pharmaceuticals85 %

Prescription products used for pregnancy prevention and treatment of women’s health infections.

Telehealth-enabled access10 %

Digital and remote channels used to support patient access and prescribing for PHEXXI.

Commercialization and promotion5 %

Sales, marketing, and distribution activities supporting approved products.

Asiakkaat

Evofem sells primarily into the prescription healthcare market, where the end users are patients and the economic buyers are typically payers, distributors, pharmacies, and healthcare providers. Its products are prescribed by physicians and other clinicians, with telehealth and specialty pharmacy channels helping reach women seeking contraception or treatment for BV and trichomoniasis.

Women seeking contraception

Patients and prescribers using PHEXXI for pregnancy prevention, often valuing a non-hormonal option.

Women treated for BV and trichomoniasis

Patients prescribed SOLOSEC for bacterial vaginosis and trichomoniasis treatment.

Physicians and telehealth prescribers

Clinicians who write prescriptions and determine whether the products are adopted in practice.

Pharmacies and distributors

Channel partners that stock, dispense, and distribute the products to end users.

Payers and reimbursement gatekeepers

Insurers and benefit managers that affect patient affordability and product uptake.

Strategia

Evofem’s strategy is to keep PHEXXI and SOLOSEC commercially viable through direct marketing, telehealth access, and third-party commercialization support. The company is also focused on maintaining regulatory compliance and preserving access to contract manufacturing, distribution, and promotional partners that it does not fully control internally.

Commercialize PHEXXI more effectivelyLyhyt aikaväli

PHEXXI is a core growth driver and depends on physician and patient acceptance.

Sustain SOLOSEC sales and market accessLyhyt aikaväli

SOLOSEC provides an additional approved product and diversifies the women’s health portfolio.

Reduce dependence on third partiesKeskipitkä aikaväli

Manufacturing, distribution, and telehealth are outsourced and create execution risk.

Maantiede

The company is headquartered in the United States and the available disclosures point to a primarily U.S.-centric commercial model. Geography matters mainly through U.S. regulatory oversight, telehealth rules, reimbursement access, and the domestic physician/pharmacy distribution network rather than through a broad international footprint.

Riskit

Evofem is highly exposed to commercialization risk because its revenue depends on whether PHEXXI and SOLOSEC gain and retain market acceptance. It also faces meaningful regulatory, supply chain, and financing risk because it relies on third parties for manufacturing, distribution, and telehealth delivery while operating in a heavily regulated pharmaceutical market.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Commercial acceptance of PHEXXI1Dependence on third-party manufacturing and distribution2FDA and promotion compliance3Telehealth execution risk4Product liability and post-marketing claims5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Commercial acceptance of PHEXXIVaikutus: KorkeaTodennäköisyys: Korkea

    Revenue depends heavily on whether physicians and patients adopt the product over competing contraceptive options.

    Kohdistuu: Core product revenue

  2. Dependence on third-party manufacturing and distributionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on two contract manufacturers and has limited internal distribution capability.

    Kohdistuu: Supply continuity and product availability

  3. FDA and promotion complianceVaikutus: KorkeaTodennäköisyys: Matala

    Prescription products are subject to strict rules on labeling and off-label promotion.

    Kohdistuu: Commercialization and legal risk

  4. Telehealth execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The PHEXXI telehealth platform depends on third parties, provider participation, and favorable state rules.

    Kohdistuu: Patient access channel

  5. Product liability and post-marketing claimsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Approved healthcare products can still face lawsuits, adverse events, or market setbacks after launch.

    Kohdistuu: Litigation and reputation

Kirjanpito

Harkinnanvaraiset erät
Variable consideration reserves

Product revenue is netted for estimated chargebacks, rebates, and patient support programs.

Vaikutus: Can materially change reported net sales and gross-to-net deductions

Fair value of financial instruments

The company recognizes certain debt instruments at fair value with mark-to-market adjustments.

Vaikutus: Can create volatility in other income/expense and reported earnings

Revenue recognition and trade receivables

Prescription product sales depend on distributor sell-through and estimate-based accruals.

Vaikutus: Affects timing of revenue and allowance/reserve levels

Contingencies and indemnifications

Contractual indemnities and legal claims could require future cash outflows.

Vaikutus: May affect liabilities and cash flow if claims are triggered

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Femasys Inc

FEMY · Surgical & Medical Instruments & Apparatus

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Corvex, Inc.

MOVE · Services-Computer Processing & Data Preparation

Evotec SE

EVO · Pharmaceutical Preparations

Dare Bioscience, Inc.

DARE · Pharmaceutical Preparations

Soligenix, Inc

SNGX · Pharmaceutical Preparations

Päivitetty: 24.9.2026